COAGADEX

The first and only treatment specifically for Hereditary Factor X Deficiency

visit product’s website

Therapies

Kedrion Biopharma’s line of plasma-derived therapies is broad and diverse. With products to treat or prevent many rare diseases and conditions from hemolytic disease of the fetus and newborn to immune deficiencies to hemophilia, Kedrion Biopharma offers a wide and expanding array of treatments and therapies.

browse by therapeutic area

Rare and ultra-rare diseases / Coagulation disorders

Immunology / Neurology

Critical care

Mother and child health

Latest news about our therapies

Discover our press releases, media resources, event information and stay updated on the latest news.

Kedrion

FDA Approves Kedrion’s Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®

read the news
Kedrion

Kedrion and Biotest Finalize Yimmugo Commercialization for US

read the news
Kedrion

Kedrion Biopharma’s Focus on Advancing Patient Care in Rare Disease to be Showcased at NBDF Conference 2024

read the news

COR.0010.USA.24